載入...
In Vitro Activity of Lefamulin Against a Global Collection of Bacterial Pathogens Commonly Causing Community-Acquired Bacterial Pneumonia (CABP, SENTRY 2015)
BACKGROUND: CABP is the number one reason for death by infectious diseases worldwide and emerging resistance complicates its treatment. Lefamulin is the first semi-synthetic pleuromutilin antibiotic for IV and oral use in humans. It is currently in Phase 3 trials for the treatment of CABP in adults....
Na minha lista:
| 發表在: | Open Forum Infect Dis |
|---|---|
| Main Authors: | , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Oxford University Press
2017
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5631057/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofx163.916 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|